Anzeige
Mehr »
Login
Freitag, 07.02.2025 Börsentäglich über 12.000 News von 685 internationalen Medien
Die Zukunft ist jetzt: Wie die Robotik-Revolution den US-Aktienmarkt in den Schatten stellt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E2FW | ISIN: US87241J2033 | Ticker-Symbol: 0K30
Lang & Schwarz
07.02.25
07:00 Uhr
1,700 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
TFF PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
TFF PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,5501,85007:00
PR Newswire
24 Leser
Artikel bewerten:
(0)

TFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC Deregistration

Finanznachrichten News

FOXBOROUGH, Mass., Feb. 6, 2025 /PRNewswire/ -- TFF Pharmaceuticals, Inc. (Nasdaq: TFFP) today announced that the Company has provided notification to The Nasdaq Stock Market, LLC ("Nasdaq") of its intent to voluntarily delist the Company's common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Capital Market. The Company expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the delisting of its Common Stock on or about February 16, 2025. The removal of the Common Stock from Nasdaq will be effective 10 days after the filing of the Form 25. The Company has made no arrangements for the listing or quotation of its Common Stock on any other exchange, market or quotation medium.

The withdrawal of the Common Stock from listing and registration is being undertaken in connection with the planned the liquidation and dissolution of the Company.

Forward Looking Statements

Statements made in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our plans to wind down our operations or other statements not of historical fact. Risks that could cause actual results to differ from those expressed in these forward-looking statements include: the timing, progress and results of our planned wind down; general market conditions; and other risks described in TFF Pharmaceuticals' filings with the Securities and Exchange Commission under the heading "Risk Factors". All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. TFF Pharmaceuticals undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made except as required by law.

SOURCE TFF Pharmaceuticals

© 2025 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.